H. Whiteford, L. Degenhardt, J. Rehm, A. Baxter, A. Ferrari et al., Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010, The Lancet, vol.382, issue.9904, pp.1575-86, 2009.
DOI : 10.1016/S0140-6736(13)61611-6

R. Tandon, W. Gaebel, D. Barch, J. Bustillo, R. Gur et al., Definition and description of schizophrenia in the DSM-5, Schizophrenia Research, vol.150, issue.1, pp.3-10, 2013.
DOI : 10.1016/j.schres.2013.05.028

C. Bowie and P. Harvey, Cognition in Schizophrenia: Impairments, Determinants, and Functional Importance, Psychiatric Clinics of North America, vol.28, issue.3, pp.613-646, 2005.
DOI : 10.1016/j.psc.2005.05.004

D. Goff, C. Cather, A. Evins, D. Henderson, O. Freudenreich et al., Medical Morbidity and Mortality in Schizophrenia, The Journal of Clinical Psychiatry, vol.66, issue.02, 2005.
DOI : 10.4088/JCP.v66n0205

D. Robinson, M. Woerner, M. Mcmeniman, A. Mendelowitz, and R. Bilder, Symptomatic and Functional Recovery From a First Episode of Schizophrenia or Schizoaffective Disorder, American Journal of Psychiatry, vol.161, issue.3, pp.473-482, 2004.
DOI : 10.1176/appi.ajp.161.3.473

S. Leucht, C. Corves, D. Arbter, R. Engel, C. Li et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009.
DOI : 10.1016/S0140-6736(08)61764-X

P. Stephen and J. Williamson, DRUG-INDUCED PARKINSONISM IN THE ELDERLY, The Lancet, vol.324, issue.8411, 1984.
DOI : 10.1016/S0140-6736(84)91516-2

J. López-sendón, M. Mena, and J. De-yébenes, Drug-Induced Parkinsonism in the Elderly, Drugs & Aging, vol.81, issue.960, pp.105-123, 2012.
DOI : 10.2165/11598540-000000000-00000

J. Bower, D. Maraganore, S. Mcdonnell, and W. Rocca, Incidence and distribution of parkinsonism in Olmsted County, Minnesota, Neurology Apr, vol.1252, issue.6, pp.1976-19901214, 1999.

R. Hausner, Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment, J Clin Psychiatry, vol.44, issue.1, pp.13-19, 1983.

M. Tinazzi, A. Antonini, T. Bovi, I. Pasquin, M. Steinmayr et al., Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism, Journal of Neurology, vol.12, issue.Suppl 7, 2009.
DOI : 10.1007/s00415-009-5039-0

M. Tinazzi, S. Ottaviani, I. Isaias, I. Pasquin, M. Steinmayr et al., I]FP-CIT SPET imaging in drug-induced Parkinsonism, Movement Disorders, vol.40, issue.13, pp.1825-1834, 2008.
DOI : 10.1002/mds.22098

M. Tinazzi, A. Cipriani, A. Matinella, A. Cannas, P. Solla et al., 123 I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism, Schizophr Res, 2012.

M. Mena, G. De-yébenes, M. Tabernero, C. Casarejos, M. Pardo et al., Effects of Calcium Antagonists on the Dopamine System, Clinical Neuropharmacology, vol.18, issue.5, pp.410-436, 1995.
DOI : 10.1097/00002826-199510000-00004

H. Rollema, M. Skolnik, D. Engelbronner, J. Igarashi, K. Usuki et al., MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies, J Pharmacol Exp Ther, vol.268, issue.1, pp.380-387, 1994.

G. Madeo, T. Schirinzi, G. Martella, E. Latagliata, F. Puglisi et al., heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity, Movement Disorders, vol.132, issue.1, pp.41-53, 2014.
DOI : 10.1002/mds.25724

B. Palmer, R. Heaton, J. Paulsen, J. Kuck, D. Braff et al., Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, pp.437-483, 1997.
DOI : 10.1037/0894-4105.11.3.437

M. Green, Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder, The Journal of Clinical Psychiatry, vol.67, issue.10, p.12, 2006.
DOI : 10.4088/JCP.1006e12

J. Schaefer, E. Giangrande, D. Weinberger, D. Dickinson, M. Green et al., The global cognitive impairment in schizophrenia: consistent over decades and around the world Social cognition in schizophrenia, Schizophr Res. Nat Rev Neurosci, vol.150, issue.20, pp.42-50, 2013.

A. Maat, A. Fett, and E. Derks, Social cognition and quality of life in schizophrenia, Schizophrenia Research, vol.137, issue.1-3, pp.1-3212
DOI : 10.1016/j.schres.2012.02.017

S. Siris, Depression in Schizophrenia: Perspective in the Era of ???Atypical??? Antipsychotic Agents, American Journal of Psychiatry, vol.157, issue.9, pp.1379-89, 2000.
DOI : 10.1176/appi.ajp.157.9.1379

S. C. Dépression-et-schizophrénie-de-leon, J. Diaz, F. French, L. Gray, C. Leonard et al., Les maladies dépressives Paris : Flammarion, Médecine-sciences A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence. JAMA Psychiatry, pp.133-42135, 2003.

S. Tarbox and M. Pogue-geile, Development of social functioning in preschizophrenia children and adolescents: A systematic review., Psychological Bulletin, vol.134, issue.4, pp.561-83, 2008.
DOI : 10.1037/0033-2909.34.4.561

M. Penttilä, E. Jääskeläinen, N. Hirvonen, M. Isohanni, and J. Miettunen, Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis, The British Journal of Psychiatry, vol.205, issue.2
DOI : 10.1192/bjp.bp.113.127753

O. Howes, J. Kambeitz, E. Kim, D. Stahl, M. Slifstein et al., The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment, Archives of General Psychiatry, vol.69, issue.8, pp.776-86, 2012.
DOI : 10.1001/archgenpsychiatry.2012.169

O. Howes, A. Egerton, V. Allan, P. Mcguire, P. Stokes et al., Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging, Current Pharmaceutical Design, vol.15, issue.22, pp.2550-2559, 2009.
DOI : 10.2174/138161209788957528

URL : http://doi.org/10.2174/138161209788957528

M. Laruelle, A. Abi-dargham, R. Gil, L. Kegeles, and R. Innis, Increased dopamine transmission in schizophrenia: relationship to illness phases, Biological Psychiatry, vol.46, issue.1, pp.56-72, 1999.
DOI : 10.1016/S0006-3223(99)00067-0

O. Howes, S. Bose, F. Turkheimer, I. Valli, A. Egerton et al., Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study, Molecular Psychiatry, vol.16, issue.9, 2011.
DOI : 10.1001/archpsyc.59.10.921

S. Vuillermot, L. Weber, J. Feldon, and U. Meyer, A Longitudinal Examination of the Neurodevelopmental Impact of Prenatal Immune Activation in Mice Reveals Primary Defects in Dopaminergic Development Relevant to Schizophrenia, Journal of Neuroscience, vol.30, issue.4, pp.1270-87, 2010.
DOI : 10.1523/JNEUROSCI.5408-09.2010

B. El-khodor and P. Boksa, Effects of birth insult and stress at adulthood on in vivo tyrosine hydroxylase and tryptophan hydroxylase activities in rat brain El-Khodor BF, Boksa P. Differential vulnerability of male versus female rats to long-term effects of birth insult on brain catecholamine levels, Exp Neurol, vol.47182, issue.361, pp.87-9208, 2003.

W. Brake, M. Noel, P. Boksa, and A. Gratton, Influence of perinatal factors on the nucleus accumbens dopamine response to repeated stress during adulthood: an electrochemical study in the rat, Neuroscience, vol.77, issue.4, pp.1067-76, 1997.
DOI : 10.1016/S0306-4522(96)00543-X

E. Cantor-graae and J. Selten, Schizophrenia and Migration: A Meta-Analysis and Review, American Journal of Psychiatry, vol.162, issue.1, pp.12-24, 2005.
DOI : 10.1176/appi.ajp.162.1.12

URL : http://doi.org/10.1176/appi.ajp.162.1.12

L. Krabbendam and J. Van-os, Schizophrenia and Urbanicity: A Major Environmental Influence--Conditional on Genetic Risk, Schizophrenia Bulletin, vol.31, issue.4, pp.795-804, 2005.
DOI : 10.1093/schbul/sbi060

URL : http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/31/4/795

F. Varese, F. Smeets, M. Drukker, R. Lieverse, T. Lataster et al., Childhood Adversities Increase the Risk of Psychosis: A Meta-analysis of Patient-Control, Prospective- and Cross-sectional Cohort Studies, Schizophrenia Bulletin, vol.38, issue.4, pp.661-71
DOI : 10.1093/schbul/sbs050

O. Howes, A. Montgomery, M. Asselin, R. Murray, I. Valli et al., Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia, Archives of General Psychiatry, vol.66, issue.1, 2009.
DOI : 10.1001/archgenpsychiatry.2008.514

I. Boileau, A. Dagher, M. Leyton, R. Gunn, G. Baker et al., Modeling Sensitization to Stimulants in Humans, Archives of General Psychiatry, vol.63, issue.12, pp.1386-951109, 2006.
DOI : 10.1001/archpsyc.63.12.1386

M. Talkowski, G. Kirov, M. Bamne, L. Georgieva, G. Torres et al., A network of dopaminergic gene variations implicated as risk factors for schizophrenia, Human Molecular Genetics, vol.17, issue.5, pp.747-58, 2008.
DOI : 10.1093/hmg/ddm347

L. Weiss, Autism genetics: emerging data from genome-wide copy-number and single nucleotide polymorphism scans, Expert Review of Molecular Diagnostics, vol.9, issue.8, pp.795-803, 2009.
DOI : 10.1586/erm.09.59

H. Mefford, H. Muhle, P. Ostertag, V. Spiczak, S. Buysse et al., Genome-Wide Copy Number Variation in Epilepsy: Novel Susceptibility Loci in Idiopathic Generalized and Focal Epilepsies, PLoS Genetics, vol.23, issue.5, p.1000962, 2010.
DOI : 10.1371/journal.pgen.1000962.t002

E. Emamian, AKT/GSK3 signaling pathway and schizophrenia, Frontiers in Molecular Neuroscience, vol.5, p.33, 2012.
DOI : 10.3389/fnmol.2012.00033

K. Albert, H. Hemmings, A. Adamo, S. Potkin, S. Akbarian et al., Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry, pp.705-717, 2002.

R. Bentall, G. Rowse, N. Shryane, P. Kinderman, R. Howard et al., The Cognitive and Affective Structure of Paranoid Delusions, Archives of General Psychiatry, vol.66, issue.3, pp.236-283, 2009.
DOI : 10.1001/archgenpsychiatry.2009.1

L. De-lau and M. Breteler, Epidemiology of Parkinson's disease, The Lancet Neurology, vol.5, issue.6, 2006.
DOI : 10.1016/S1474-4422(06)70471-9

M. De-rijk, L. Launer, K. Berger, M. Breteler, J. Dartigues et al., Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Do environmental toxins cause Parkinson's disease? A critical review, Neurology. Neurology, vol.5440, issue.5210, pp.21-23, 1990.

J. Langston, P. Ballard, H. Chen, M. Weisskopf, O. Reilly et al., Parkinson's disease in a chemist working with 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine Pesticide exposure and risk for Parkinson's disease, N Engl J Med Ann Neurol, vol.30960, issue.52, pp.310197-203, 1983.

V. Bonifati, Genetics of Parkinson's disease ??? state of the art, 2013, Parkinsonism & Related Disorders, vol.20, issue.1, pp.23-28, 2013.
DOI : 10.1016/S1353-8020(13)70009-9

A. Schapira, D. Chiasserini, T. Beccari, and L. Parnetti, Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment, Movement Disorders, vol.137, issue.6, p.2016
DOI : 10.1016/j.nbd.2015.09.006

A. Singleton, M. Farrer, and V. Bonifati, The genetics of Parkinson's disease: Progress and therapeutic implications, Movement Disorders, vol.47, issue.Suppl, pp.14-23, 2013.
DOI : 10.1002/mds.25249

R. Postuma, D. Aarsland, P. Barone, D. Burn, C. Hawkes et al., Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease, Movement Disorders, vol.133, issue.Pt 2, pp.617-643, 2012.
DOI : 10.1002/mds.24996

O. Hornykiewicz, Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms, Adv Neurol, vol.60, pp.140-147, 1993.

G. Deuschl, P. Bain, and M. Brin, Consensus Statement of the Movement Disorder Society on Tremor, Movement Disorders, vol.10, issue.S3, pp.2-23, 1998.
DOI : 10.1002/mds.870131303

. Viallet, Maladie de Parkinson idiopathique??: aspects cliniques, diagnostiques et th??rapeutiques, EMC - Neurologie, vol.7, issue.2, pp.1-30
DOI : 10.1016/S0246-0378(10)51548-3

G. Ross, H. Petrovitch, R. Abbott, C. Tanner, J. Popper et al., Association of olfactory dysfunction with risk for future Parkinson's disease, Annals of Neurology, vol.253, issue.2, pp.167-73, 2008.
DOI : 10.1002/ana.21291

V. Iodice, D. Low, E. Vichayanrat, and C. Mathias, Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences, Journal of the Neurological Sciences, vol.310, issue.1-2, pp.133-141, 2011.
DOI : 10.1016/j.jns.2011.07.014

F. Stocchi, L. Barbato, G. Nordera, A. Berardelli, and S. Ruggieri, Sleep disorders in Parkinson???s disease, Journal of Neurology, vol.245, issue.S1, pp.15-18, 1998.
DOI : 10.1007/PL00007731

Y. Okuma, Freezing of gait and falls in Parkinson's disease, J Park Dis, vol.4, issue.2, pp.255-60, 2014.

S. Pinto, A. Ghio, B. Teston, and F. Viallet, [Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria], Rev Neurol, 2010.

A. Owen, Cognitive Dysfunction in Parkinson???s Disease: The Role of Frontostriatal Circuitry, The Neuroscientist, vol.35, issue.15
DOI : 10.1177/1073858404266776

R. Barker and C. Williams-gray, Mild Cognitive Impairment and Parkinson???s Disease - Something to Remember, Journal of Parkinson's Disease, vol.4, issue.4, pp.651-657, 2014.
DOI : 10.3233/JPD-140427

URL : http://www.repository.cam.ac.uk/handle/1810/245834

Y. Bocanegra, N. Trujillo-orrego, and D. Pineda, Dementia and mild cognitive impairment in Parkinson's disease: a review]. Rev Neurol, pp.555-69, 2014.

G. Linazasoro, New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity, Trends in Pharmacological Sciences, vol.26, issue.8, pp.391-398, 2005.
DOI : 10.1016/j.tips.2005.06.007

J. Segura-aguilar, I. Paris, P. Muñoz, E. Ferrari, L. Zecca et al., Protective and toxic roles of dopamine in Parkinson's disease, Journal of Neurochemistry, vol.25, issue.6, pp.898-915
DOI : 10.1111/jnc.12686

D. Sulzer and L. Zecca, Intraneuronal dopamine-quinone synthesis: A review, Neurotoxicity Research, vol.37, issue.6, 2000.
DOI : 10.1007/BF03033289

S. Jana, A. Maiti, M. Bagh, K. Banerjee, A. Das et al., Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: Implications in Parkinson's disease, Brain Research, vol.1139, pp.195-200, 2007.
DOI : 10.1016/j.brainres.2006.09.100

S. Jana, M. Sinha, C. D. Roy, T. Banerjee, K. Munshi et al., Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1812, issue.6, pp.663-73, 1812.
DOI : 10.1016/j.bbadis.2011.02.013

S. Plum, S. Helling, C. Theiss, R. Leite, C. May et al., Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis, Journal of Proteomics, vol.94, pp.202-208, 2013.
DOI : 10.1016/j.jprot.2013.07.015

J. Spencer, P. Jenner, S. Daniel, A. Lees, D. Marsden et al., Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species, Journal of Neurochemistry, vol.71, issue.5, pp.2112-2134, 1998.
DOI : 10.1046/j.1471-4159.1998.71052112.x

A. Schapira, Mitochondria in the aetiology and pathogenesis of Parkinson's disease, The Lancet Neurology, vol.7, issue.1, pp.97-109, 2008.
DOI : 10.1016/S1474-4422(07)70327-7

A. Schapira, Mitochondrial complex I deficiency in Parkinson's disease, Adv Neurol, vol.60, pp.288-91, 1993.

E. Hattingen, J. Magerkurth, U. Pilatus, A. Mozer, C. Seifried et al., Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease, Brain, vol.132, issue.12, pp.3285-97, 2009.
DOI : 10.1093/brain/awp293

J. Blesa and S. Przedborski, Parkinson's disease: animal models and dopaminergic cell vulnerability Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease, Front Neuroanat. Gene, vol.8532, issue.841, pp.15518-15541, 2013.
DOI : 10.3389/fnana.2014.00155

URL : http://doi.org/10.3389/fnana.2014.00155

C. Barcia, F. Barreiro, A. Poza, M. Herrero, and M. , Parkinson's disease and inflammatory changes, Neurotoxicity Research, vol.17, issue.6, pp.411-419, 2003.
DOI : 10.1007/BF03033170

P. Mcgeer, S. Itagaki, B. Boyes, and E. Mcgeer, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, vol.38, issue.8, pp.1285-91, 1988.
DOI : 10.1212/WNL.38.8.1285

M. Block, L. Zecca, and J. Hong, Microglia-mediated neurotoxicity: uncovering the molecular mechanisms, Nature Reviews Neuroscience, vol.13, issue.1, pp.57-69, 2007.
DOI : 10.1523/JNEUROSCI.4306-04.2005

M. Wilhelmus, P. Nijland, B. Drukarch, H. De-vries, and J. Van-horssen, Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders, Free Radical Biology and Medicine, vol.53, issue.4, pp.983-92, 2012.
DOI : 10.1016/j.freeradbiomed.2012.05.040

H. Braak and E. Braak, Pathoanatomy of Parkinson???s disease, Journal of Neurology, vol.247, issue.S2, pp.3-10, 2000.
DOI : 10.1007/PL00007758

K. Vekrellis, M. Xilouri, E. Emmanouilidou, H. Rideout, and L. Stefanis, Pathological roles of ??-synuclein in neurological disorders, The Lancet Neurology, vol.10, issue.11, pp.1015-1040, 2011.
DOI : 10.1016/S1474-4422(11)70213-7

M. Chartier-harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay et al., ??-synuclein locus duplication as a cause of familial Parkinson's disease, The Lancet, vol.364, issue.9440, pp.1167-1176, 2004.
DOI : 10.1016/S0140-6736(04)17103-1

J. Simón-sánchez, C. Schulte, J. Bras, M. Sharma, J. Gibbs et al., Genome-wide association study reveals genetic risk underlying Parkinson's disease, Nature Genetics, vol.105, issue.12, 2009.
DOI : 10.1038/ng.487

H. Lashuel, C. Overk, A. Oueslati, and E. Masliah, The many faces of ??-synuclein: from structure and toxicity to therapeutic target, Nature Reviews Neuroscience, vol.418, issue.1, pp.38-48, 2013.
DOI : 10.1038/nrn3406

L. Bianco, C. Ridet, J. Schneider, B. Deglon, N. Aebischer et al., ??-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proceedings of the National Academy of Sciences, vol.99, issue.16, pp.10813-10821, 2002.
DOI : 10.1073/pnas.152339799

L. Hsu, Y. Sagara, A. Arroyo, E. Rockenstein, A. Sisk et al., ??-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress, The American Journal of Pathology, vol.157, issue.2, pp.401-411, 2000.
DOI : 10.1016/S0002-9440(10)64553-1

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850140

M. Hashimoto, K. Kawahara, P. Bar-on, E. Rockenstein, L. Crews et al., The Role of ??-Synuclein Assembly and Metabolism in the Pathogenesis of Lewy Body Disease, Journal of Molecular Neuroscience, vol.24, issue.3, pp.343-52, 2004.
DOI : 10.1385/JMN:24:3:343

M. Alim, Q. Ma, K. Takeda, T. Aizawa, M. Matsubara et al., Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein, J Alzheimers Dis JAD, 2004.

D. Scott, I. Tabarean, Y. Tang, A. Cartier, E. Masliah et al., A Pathologic Cascade Leading to Synaptic Dysfunction in ??-Synuclein-Induced Neurodegeneration, Journal of Neuroscience, vol.30, issue.24, pp.8083-95, 2010.
DOI : 10.1523/JNEUROSCI.1091-10.2010

J. Li, E. Englund, H. Widner, S. Rehncrona, A. Björklund et al., Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease, Movement Disorders, vol.24, issue.8, pp.1091-1097, 2010.
DOI : 10.1002/mds.23012

H. Braak, R. De-vos, J. Bohl, D. Tredici, and K. , Gastric ??-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology, Neuroscience Letters, vol.396, issue.1, pp.67-72, 2006.
DOI : 10.1016/j.neulet.2005.11.012

E. Angot, J. Steiner, C. Hansen, J. Li, and P. Brundin, Are synucleinopathies prion-like disorders? Lancet Neurol, pp.1128-1166, 2010.
DOI : 10.1016/s1474-4422(10)70213-1

C. Hawkes, D. Tredici, K. Braak, and H. , Parkinson's disease: a dual-hit hypothesis, Neuropathology and Applied Neurobiology, vol.70, issue.6, pp.599-614, 2007.
DOI : 10.1007/s007050050016

G. Alexander and M. Crutcher, Functional architecture of basal ganglia circuits: neural substrates of parallel processing, Trends in Neurosciences, vol.13, issue.7, pp.266-71, 1990.
DOI : 10.1016/0166-2236(90)90107-L

W. Nauta and V. Domesick, Afferent and Efferent Relationships of the Basal Ganglia, Ciba Found Symp, vol.15, pp.3-29, 1984.
DOI : 10.1002/9780470720882.ch2

R. Bordet, Central dopamine receptors: general considerations (Part 1)], Rev Neurol, vol.160, pp.8-9862, 2004.

R. Kuepper, M. Skinbjerg, and A. Abi-dargham, The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course, Handb Exp Pharmacol, issue.212, pp.1-26, 2012.
DOI : 10.1007/978-3-642-25761-2_1

P. Sokoloff and J. Schwartz, Novel dopamine receptors half a decade later, Trends in Pharmacological Sciences, vol.16, issue.8, pp.270-275, 1995.
DOI : 10.1016/S0165-6147(00)89044-6

J. Mink, THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS, Progress in Neurobiology, vol.50, issue.4
DOI : 10.1016/S0301-0082(96)00042-1

J. Saint-cyr, Frontal-striatal circuit functions: Context, sequence, and consequence, Journal of the International Neuropsychological Society, vol.9, issue.01, pp.103-130, 2003.
DOI : 10.1017/S1355617703910125

R. Albin, A. Young, and J. Penney, The functional anatomy of basal ganglia disorders. Trends Neurosci, pp.366-75, 1989.

A. Parent, Extrinsic connections of the basal ganglia. Trends Neurosci, pp.254-262, 1990.

Y. Temel, A. Blokland, H. Steinbusch, and V. Visser-vandewalle, The functional role of the subthalamic nucleus in cognitive and limbic circuits, Progress in Neurobiology, vol.76, issue.6, pp.393-413, 2005.
DOI : 10.1016/j.pneurobio.2005.09.005

R. Albin, A. Young, and J. Penney, The functional anatomy of disorders of the basal ganglia, Trends in Neurosciences, vol.18, issue.2, pp.63-67, 1995.
DOI : 10.1016/0166-2236(95)80020-3

M. Delong, Primate models of movement disorders of basal ganglia origin. Trends Neurosci, pp.281-286, 1990.

O. Aizman, H. Brismar, P. Uhlén, E. Zettergren, A. Levey et al., Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons, Nat Neurosci, vol.3, issue.3, pp.226-256, 2000.

A. Parent, M. Lévesque, and M. Parent, A re-evaluation of the current model of the basal ganglia, Parkinsonism & Related Disorders, vol.7, issue.3, pp.193-201, 2001.
DOI : 10.1016/S1353-8020(00)00058-4

R. Erro, K. Bhatia, and M. Tinazzi, Parkinsonism following neuroleptic exposure: A double-hit hypothesis? Mov Disord Off J Mov Disord Soc, pp.780-785, 2015.
DOI : 10.1002/mds.26209

F. Diaz-corrales, S. Sanz-viedma, D. Garcia-solis, T. Escobar-delgado, and P. Mir, Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson???s disease, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.Suppl 7, pp.556-64, 2010.
DOI : 10.1007/s00259-009-1289-4

J. Kim, Y. Oh, Y. Kim, D. Yang, Y. Chung et al., Combined use of 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): A 2-year follow-up study, Archives of Gerontology and Geriatrics, vol.56, issue.1, pp.124-132, 2013.
DOI : 10.1016/j.archger.2012.05.001

A. Foubert-samier, C. Helmer, F. Perez, L. Goff, M. Auriacombe et al., Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort, Neurology, vol.79, issue.15, pp.1615-1636, 2009.
DOI : 10.1212/WNL.0b013e31826e25ce

M. Alvarez and V. Evidente, Understanding drug-induced parkinsonism: Separating pearls from oy-sters, Neurology, vol.70, issue.8, pp.32-34, 2008.
DOI : 10.1212/01.wnl.0000302255.49113.51

W. Knol, C. Keijsers, P. Jansen, and R. Van-marum, Systematic Evaluation of Rating Scales for Drug-Induced Parkinsonism and Recommendations for Future Research, Journal of Clinical Psychopharmacology, vol.30, issue.1, 2010.
DOI : 10.1097/JCP.0b013e3181c914b3

. Simpson, G. Simpson, and J. Angus, A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS, Acta Psychiatrica Scandinavica, vol.45, issue.S212, pp.11-19, 1970.
DOI : 10.1111/j.1600-0447.1970.tb02066.x

P. Blanchet and P. Rompré, Clinimetric Evaluation of the Simpson-Angus Scale in Older Adults With Schizophrenia, Journal of Clinical Psychopharmacology, vol.34, issue.1, pp.36-45, 2014.
DOI : 10.1097/JCP.0b013e3182a6a2e3

S. Janno, M. Holi, K. Tuisku, and K. Wahlbeck, Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population, BMC Neurology, vol.14, issue.1, p.5, 2005.
DOI : 10.1176/jnp.14.3.329

H. Uchida, H. Takeuchi, A. Graff-guerrero, T. Suzuki, K. Watanabe et al., Dopamine D2 Receptor Occupancy and Clinical Effects, Journal of Clinical Psychopharmacology, vol.31, issue.4, pp.497-502, 2011.
DOI : 10.1097/JCP.0b013e3182214aad

J. Morley, S. Pawlowski, A. Kesari, I. Maina, A. Pantelyat et al., Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism, Parkinsonism & Related Disorders, vol.20, issue.7, pp.738-780
DOI : 10.1016/j.parkreldis.2014.03.024

G. Meredith, R. Switzer, and T. Napier, Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum, Brain Research, vol.995, issue.1, pp.14-22, 2004.
DOI : 10.1016/j.brainres.2003.09.040

K. Veitch and L. Hue, Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism, Mol Pharmacol, vol.45, issue.1, pp.158-63, 1994.

M. Goldberg, S. Fleming, J. Palacino, C. Cepeda, H. Lam et al., Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons, Journal of Biological Chemistry, vol.278, issue.44, pp.43628-43663, 2003.
DOI : 10.1074/jbc.M308947200

A. Serrano, J. Menéndez, M. Casarejos, R. Solano, E. Gallego et al., Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice, Neuropharmacology, vol.49, issue.2, pp.208-227, 2005.
DOI : 10.1016/j.neuropharm.2005.03.003

D. Choi, M. Liu, R. Hunter, W. Cass, J. Pandya et al., Striatal Neuroinflammation Promotes Parkinsonism in Rats, PLoS ONE, vol.16, issue.5, p.5482, 2009.
DOI : 10.1371/journal.pone.0005482.s003

L. Greenbaum and B. Lerer, Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes, Front Neurol, vol.6, p.27, 2015.

P. Cesaro and L. Defebvre, Traitement m??dicamenteux de la maladie de Parkinson ?? la phase pr??coce (de novo et ????lune de miel????), Revue Neurologique, vol.170, issue.4, pp.237-283
DOI : 10.1016/j.neurol.2013.10.015

C. Haaxma, M. Horstink, J. Zijlmans, W. Lemmens, B. Bloem et al., Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson???s Disease1, Journal of Parkinson's Disease, vol.5, issue.4, pp.847-53, 2015.
DOI : 10.3233/JPD-150532

S. Fahn, The spectrum of levodopa-induced dyskinesias, Ann Neurol, vol.47, issue.4, pp.2-9, 2000.

A. Nadjar, C. Gerfen, and E. Bezard, Priming for l-dopa-induced dyskinesia in Parkinson???s disease: A feature inherent to the treatment or the disease?, Progress in Neurobiology, vol.87, issue.1, pp.1-9, 2009.
DOI : 10.1016/j.pneurobio.2008.09.013

M. Cenci and M. Lundblad, Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia, Journal of Neurochemistry, vol.25, issue.2, pp.381-92, 2006.
DOI : 10.1016/0166-2236(90)90112-N

P. Calabresi, D. Filippo, M. Ghiglieri, V. Tambasco, N. Picconi et al., Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap, The Lancet Neurology, vol.9, issue.11, 2010.
DOI : 10.1016/S1474-4422(10)70218-0

B. Picconi, V. Paillé, V. Ghiglieri, V. Bagetta, I. Barone et al., l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation, Neurobiology of Disease, vol.29, issue.2, 2008.
DOI : 10.1016/j.nbd.2007.10.001

D. Vijayakumar and J. Jankovic, Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia, Drugs, vol.16, issue.4, pp.759-77
DOI : 10.1007/s40265-016-0566-3

S. Fox, R. Chuang, and J. Brotchie, Serotonin and Parkinson's disease: On movement, mood, and madness, Movement Disorders, vol.21, issue.Part 12, pp.1255-66, 2009.
DOI : 10.1002/mds.22473

A. Muñoz, T. Carlsson, E. Tronci, D. Kirik, A. Björklund et al., Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model, Experimental Neurology, vol.219, issue.1, pp.298-307, 2009.
DOI : 10.1016/j.expneurol.2009.05.033

C. Simonin, M. Tir, D. Devos, A. Kreisler, K. Dujardin et al., Reduced levodopa-induced complications after 5??years of subthalamic stimulation in Parkinson???s disease: a second honeymoon, Journal of Neurology, vol.66, issue.Pt 11, pp.1736-1777, 2009.
DOI : 10.1007/s00415-009-5195-2

D. Owens, E. Johnstone, and C. Frith, Spontaneous Involuntary Disorders of Movement, Archives of General Psychiatry, vol.39, issue.4, pp.452-61, 1982.
DOI : 10.1001/archpsyc.1982.04290040052008

J. Friedman, Historical perspective on movement disorders, J Clin Psychiatry, vol.65, issue.9, pp.3-8, 2004.

C. Aquino and A. Lang, Tardive dyskinesia syndromes: current concepts, Parkinsonism & Related Disorders, vol.20, issue.1, pp.113-117
DOI : 10.1016/S1353-8020(13)70028-2

G. W. Guy and W. E. , Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76 -338), 1976.

N. Schooler and J. Kane, Research diagnoses for tardive dyskinesia, Arch Gen Psychiatry, 1982.

R. Bhidayasiri, S. Fahn, W. Weiner, G. Gronseth, K. Sullivan et al., Evidencebased guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology Jul, vol.3081, issue.5, pp.463-472, 2013.

S. Pappa, S. Tsouli, G. Apostolou, V. Mavreas, and S. Konitsiotis, Effects of Amantadine on Tardive Dyskinesia, Clinical Neuropharmacology, vol.33, issue.6, 2010.
DOI : 10.1097/WNF.0b013e3181ffde32

C. Mentzel, D. Tenback, M. Tijssen, V. Visser-vandewalle, and P. Van-harten, Efficacy and Safety of Deep Brain Stimulation in Patients With Medication-Induced Tardive Dyskinesia and/or Dystonia, The Journal of Clinical Psychiatry, vol.73, issue.11, pp.1434-1442, 2012.
DOI : 10.4088/JCP.12r07643

C. Li, K. Chou, T. Su, C. Huang, M. Chen et al., Gray Matter Abnormalities in Schizophrenia Patients with Tardive Dyskinesia: A Magnetic Resonance Imaging Voxel-Based Morphometry Study, PLoS ONE, vol.68, issue.8, p.71034, 2013.
DOI : 10.1371/journal.pone.0071034.t003

A. Cerasa, D. Messina, P. Pugliese, M. Morelli, P. Lanza et al., Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study, Movement Disorders, vol.72, issue.5, pp.807-819, 2011.
DOI : 10.1002/mds.23660

T. Barnes, The Barnes Akathisia Rating Scale???Revisited, Journal of Psychopharmacology, vol.144, issue.4, 2003.
DOI : 10.1177/0269881103174013

F. Berna, D. Misdrahi, L. Boyer, B. Aouizerate, L. Brunel et al., Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset, Schizophr Res, vol.169, pp.1-3255, 2015.

I. Bratti, J. Kane, and S. Marder, Chronic Restlessness With Antipsychotics, American Journal of Psychiatry, vol.164, issue.11, pp.1648-54, 2007.
DOI : 10.1176/appi.ajp.2007.07071150

URL : http://doi.org/10.1176/appi.ajp.2007.07071150

S. Kapur, R. Zipursky, C. Jones, R. G. Houle, and S. , Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia, American Journal of Psychiatry, vol.157, issue.4, pp.514-534, 2000.
DOI : 10.1176/appi.ajp.157.4.514

P. Sachdev and M. Brüne, Animal models of acute drug-induced akathisia ??? a review, Neuroscience & Biobehavioral Reviews, vol.24, issue.3, pp.269-77, 2000.
DOI : 10.1016/S0149-7634(99)00069-X

V. Mattay, C. D. Hirsch, S. Weinberger, and D. , Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia, in Schizophrenia, Blackwell Scientific Science, pp.552-572, 2003.
DOI : 10.1002/9780470987353.ch28

T. Barnes, A rating scale for drug-induced akathisia, The British Journal of Psychiatry, vol.154, issue.5, 1989.
DOI : 10.1192/bjp.154.5.672

S. Janno, M. Holi, K. Tuisku, and K. Wahlbeck, Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia, European Neuropsychopharmacology, vol.15, issue.1, 2005.
DOI : 10.1016/j.euroneuro.2004.05.003

D. Miller, S. Caroff, S. Davis, R. Rosenheck, J. Mcevoy et al., Extrapyramidal side-effects of antipsychotics in a randomised trial, The British Journal of Psychiatry, vol.193, issue.4, pp.279-88, 2008.
DOI : 10.1192/bjp.bp.108.050088

D. Casey, T. Widiger, A. Frances, H. Pincus, M. First et al., Neuroleptic-induced acute dystonia American Psychiatric Association, DSM-IV source book, pp.545-559, 1994.

P. Van-harten, H. Hoek, and R. Kahn, Acute dystonia induced by drug treatment, BMJ, 1999.

T. Satterthwaite, D. Wolf, R. Rosenheck, R. Gur, and S. Caroff, A Meta-Analysis of the Risk of Acute Extrapyramidal Symptoms With Intramuscular Antipsychotics for the Treatment of Agitation, The Journal of Clinical Psychiatry, vol.69, issue.12, pp.1869-79, 2008.
DOI : 10.4088/JCP.v69n1204

F. Schürhoff, G. Fond, F. Berna, E. Bulzacka, J. Vilain et al., A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap, European Psychiatry, vol.30, issue.6, pp.728-763, 2015.
DOI : 10.1016/j.eurpsy.2015.05.004

S. Kay, A. Fiszbein, and L. Opler, The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-76, 1987.
DOI : 10.1093/schbul/13.2.261

URL : http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/13/2/261

R. Young, J. Biggs, V. Ziegler, and D. Meyer, A rating scale for mania: reliability, validity and sensitivity, The British Journal of Psychiatry, vol.133, issue.5, pp.429-464, 1978.
DOI : 10.1192/bjp.133.5.429

D. Addington, J. Addington, and E. Maticka-tyndale, Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry, pp.39-44, 1993.

M. Byerly, P. Nakonezny, and A. Rush, The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder, Schizophrenia Research, vol.100, issue.1-3, pp.1-360, 2008.
DOI : 10.1016/j.schres.2007.12.470

S. Leucht, M. Samara, S. Heres, M. Patel, S. Woods et al., Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method, Schizophrenia Bulletin, vol.40, issue.2, pp.314-340, 2014.
DOI : 10.1093/schbul/sbu001

T. Hansen, D. Casey, and W. Hoffman, Neuroleptic Intolerance, Schizophrenia Bulletin, vol.23, issue.4, pp.567-82, 1997.
DOI : 10.1093/schbul/23.4.567

S. Janno, M. Holi, K. Tuisku, and K. Wahlbeck, Prevalence of Neuroleptic-Induced Movement Disorders in Chronic Schizophrenia Inpatients, American Journal of Psychiatry, vol.161, issue.1, pp.160-163, 2004.
DOI : 10.1176/appi.ajp.161.1.160

M. Moreno-calvete, Prevalence of extrapyramidal effects by neuroleptics in admitted people with schizophrenia]. Enferm Clínica, pp.114-121, 2013.

P. Czobor, R. Van-dorn, L. Citrome, R. Kahn, W. Fleischhacker et al., Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies, European Neuropsychopharmacology, vol.25, issue.8, pp.1158-66, 2015.
DOI : 10.1016/j.euroneuro.2015.04.003

J. Zhang, J. Gallego, D. Robinson, A. Malhotra, J. Kane et al., Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis, The International Journal of Neuropsychopharmacology, vol.16, issue.06, pp.1205-1223, 2013.
DOI : 10.1017/S1461145712001277

L. Docx, M. Morrens, C. Bervoets, W. Hulstijn, E. Fransen et al., Parsing the components of the psychomotor syndrome in schizophrenia, Acta Psychiatrica Scandinavica, vol.25, issue.4, 2012.
DOI : 10.1111/j.1600-0447.2012.01846.x

J. Rybakowski, K. Vansteelandt, A. Remlinger-molenda, W. Fleischhacker, R. Kahn et al., Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST, European Neuropsychopharmacology, vol.24, issue.9, pp.1500-1505, 2014.
DOI : 10.1016/j.euroneuro.2014.07.001

D. Tarsy and R. Baldessarini, Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord Off J Mov Disord Soc, pp.589-98, 2006.

D. Robinson, M. Woerner, J. Alvir, S. Geisler, A. Koreen et al., Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder, Am J Psychiatry, vol.156, issue.4, pp.544-553, 1999.

T. Mccann, G. Boardman, E. Clark, and S. Lu, Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs, pp.622-631, 2008.

D. Velligan, P. Weiden, M. Sajatovic, J. Scott, D. Carpenter et al., The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J Clin Psychiatry, vol.70, issue.4, pp.1-46, 2009.

C. Correll and E. Schenk, Tardive dyskinesia and new antipsychotics, Curr Opin Psychiatry, 2008.
DOI : 10.1097/yco.0b013e3282f53132

A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, The World Journal of Biological Psychiatry, vol.28, issue.2, pp.2-44, 2013.
DOI : 10.4088/JCP.09m05284yel